Clinical trials: Colon Cancer Stage II
Colorectal Cancer (CRC)
Phase II, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of HLX43 (an Anti-PD-L1 ADC) in Subjects With Advanced Colorectal Cancer
The study is being conducted to to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in Patients with Advanced Colorectal Cancer (CRC)
- Trial name
- NCT07106892
- Testing
- HLX43 Dose 1;, HLX43 Dose 2;, HLX43 Dose 3;
- Where
- 2 sites in China
- Volunteers
- 60 people
- Sponsor
- Shanghai Henlius Biotech
Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix
7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)
This phase I trial is studying the side effects and best dose of giving 7-hydroxystaurosporine together with irinotecan hydrochloride in treating patients with metastatic or unresectable solid tumors, including triple-negative…
- Conditions
- Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix, Estrogen Receptor-negative Breast Cancer, Extensive Stage Small Cell Lung Cancer
- Trial name
- NCT00031681
- Testing
- 7-hydroxystaurosporine, irinotecan hydrochloride, diagnostic laboratory biomarker analysis
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer
Erlotinib and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth.
- Trial name
- NCT00049101
- Testing
- erlotinib hydrochloride, fluorouracil, leucovorin calcium
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Colorectal Cancer, Colorectal Carcinoma
Nelfinavir, a Phase I/Phase II Rectal Cancer Study
The aim is to study safety and activity of nelfinavir , added to standard chemoradiotherapy in patients with locally advanced rectal cancer.
- Conditions
- Colorectal Cancer, Colorectal Carcinoma, Colorectal Tumors, Neoplasms, Colorectal
- Trial name
- Nelfinavir (NCT00704600)
- Testing
- nelfinavir
- Where
- Netherlands
- Volunteers
- 15 people
- Sponsor
- Maastricht Radiation Oncology
Oxaliplatin-induced Peripheral Neuropathy
Effectiveness Assessment of Riluzole in the Prevention of Oxaliplatin-induced Peripheral Neuropathy.
It is a phase II trial, randomized, parallel, double blind, multicenter, comparing riluzole versus placebo. The trial population is composed of patients ≥18 years old that have developed stage II/III colorectal cancer and are…
- Trial name
- RILUZOX-01 (NCT03722680)
- Testing
- Riluzole
- Where
- 16 sites in France
- Volunteers
- 80 people
- Sponsor
- UNICANCER
Colorectal Cancer, Colorectal Carcinoma
A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer
Background: Immune-based approaches in colorectal cancer have unfortunately with the notable exception of immune checkpoint inhibition in microsatellite instable (MSI-hi) disease been largely unsuccessful.
- Conditions
- Colorectal Cancer, Colorectal Carcinoma, Colorectal Adenocarcinoma, Refractory Cancer
- Trial name
- NCT03206073
- Testing
- Durvalumab, Tremelimumab, Pexa-Vec
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
The purpose of this study is to see if Cediranib in combination with FOLFOX is effective in treating metastatic colorectal cancer and to see how it compares with Avastin (Bevacizumab) in combination with FOLFOX.
- Trial name
- HORIZON III (NCT00384176)
- Testing
- Cediranib, Bevacizumab, 5-fluorouracil ( in FOLFOX)
- Where
- 280 sites in United States, Australia and 26 more
- Volunteers
- 1,814 people
- Sponsor
- AstraZeneca
BRAF V600E, Metastatic Colorectal Cancer
A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer.
Encorafenib is currently being developed (with or without binimetinib), in combination with cetuximab, for the treatment of adult patients with B-RAF proto-oncogene, serine/threonine kinase V600E mutant (BRAF V600E) metastatic…
- Trial name
- NAUTICALCRC (NCT05004350)
- Testing
- Encorafenib, Cetuximab, FOLFIRI
- Where
- 34 sites in China
- Volunteers
- 107 people
- Sponsor
- Pierre Fabre Medicament
Metastatic Colon Cancer
Combined Use of Raltitrexed and S-1 as Treatment for Patients With Metastasizing Colorectal Cancer
The primary endpoint is to evaluate the Median disease progression free survival (mPFS).
- Trial name
- NCT02618356
- Testing
- Raltitrexed and S-1
- Where
- China
- Volunteers
- 82 people
- Sponsor
- Fudan University
BRAF V600E-mutant Metastatic Colorectal Cancer
Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal Cancer
The purpose of this study is to evaluate the efficacy and safety of the combination of study drugs encorafenib, binimetinib and cetuximab in patients who have BRAF V600 mutant metastatic colorectal cancer and have not received…
- Trial name
- ANCHOR-CRC (NCT03693170)
- Testing
- encorafenib, Binimetinib, Cetuximab
- Where
- 45 sites in United States, Austria and 7 more
- Volunteers
- 95 people
- Sponsor
- Pierre Fabre Medicament
Colorectal Cancer
Prevention of Recurrence and Metastasis of Colorectal Cancer by Comparing Huaier With Capecitabine Monotherapy
This is a prospective, multicenter, randomized, parallel controlled study to evaluate the effectiveness of Huaier Granule in preventing recurrence and metastasis after radical resection of colorectal cancer
- Trial name
- NCT06090994
- Testing
- Huaier granule, Capecitabine
- Where
- 9 sites in China
- Volunteers
- 756 people
- Sponsor
- Fudan University
Colorectal Cancer
Oxaliplatin in Treating Patients With Recurrent Metastatic Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of oxaliplatin in treating patients who have recurrent…
- Trial name
- NCT00017082
- Testing
- oxaliplatin
- Where
- 10 sites in United States
- Sponsor
- Prologue Research International
Colon Cancer, Colon Cancer (Stage II &Amp;Amp;Amp; III)
ctDNA-guided Selection of Adjuvant Chemotherapy Regimens for Elderly Colon Cancer Patients After Surgery: A Single-center, Randomized, Controlled Study
The goal of this clinical trial is to explore the disease-free survival period of elderly patients with high-risk stage II and stage III colon cancer based on ctDNA detection.
- Trial name
- ZJCH-CRCC-1 (NCT06609551)
- Testing
- 6-month adjuvant chemotherapy with 5-FU monotherapy, XELOX intensive treatment group
- Where
- China
- Volunteers
- 312 people
- Sponsor
- Zhejiang Cancer Hospital
Stage IV Colorectal Cancer
Study of FOLFIRI + Panitumumab Using Ultra-selection Technology of Patients With Stage IV Colorectal Cancer Refractory to Irinotecan Without Any Mutation on KRAS, PIK3Ca, BRAF and NRAS Genes Detected With Highly Sensitive Techniques
Open label Phase II study of FOLFIRI + Panitumumab using ultra-selection technology with next generation high sensitivity genotyping of patients with stage IV colorectal cancer refractory to irinotecan without any mutation on…
- Trial name
- ULTRA (NCT01704703)
- Testing
- panitumumab, FOLFIRI
- Where
- Spain
- Volunteers
- 72 people
- Sponsor
- Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Anal Cancer, Carcinoma of the Appendix
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
RATIONALE: Palonosetron hydrochloride may prevent nausea and vomiting caused by radiation therapy. It is not yet known whether palonosetron hydrochloride is more effective than a placebo in preventing nausea and vomiting.
- Conditions
- Anal Cancer, Carcinoma of the Appendix, Colorectal Cancer, Extrahepatic Bile Duct Cancer
- Trial name
- NCT00903396
- Testing
- palonosetron hydrochloride
- Where
- 69 sites in United States
- Volunteers
- 7 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Metastatic Colorectal Cancer
A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer
This trial is a Phase II study. The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of AK112 with or without AK117 in participants with metastatic colorectal cancer who are not suitable for surgery.
- Trial name
- NCT05382442
- Testing
- AK112, AK117, Oxaliplatin
- Where
- 4 sites in United States, China
- Volunteers
- 254 people
- Sponsor
- Akeso
Solid Tumours of Epithelial Origin, Metastatic Colorectal Cancer
Phase I / II Study of Enadenotucirev by Sub-acute Fractionated IV Dosing in Cancer Patients
This is a multicentre, open-label, Phase I/II study of enadenotucirev in patients with either solid tumour of epithelial origin not responding to standard therapy or for whom no standard treatment exists (Phase I dose escalation…
- Conditions
- Solid Tumours of Epithelial Origin, Metastatic Colorectal Cancer, Metastatic Bladder Cancer
- Trial name
- EVOLVE (NCT02028442)
- Testing
- Enadenotucirev
- Where
- 6 sites in Belgium, Spain
- Volunteers
- 61 people
- Sponsor
- Akamis Bio
Colorectal Cancer, Metastatic Cancer
Diagnostic Procedure for Identifying Patients With Metastatic Colorectal Cancer
RATIONALE: Diagnostic procedures, such as lymphography, may improve the identification of patients with metastatic colorectal cancer.
- Trial name
- NCT00003186
- Testing
- isosulfan blue, lymphangiography, sentinel lymph node biopsy
- Where
- United States
- Sponsor
- Roswell Park Cancer Institute
Metastatic Colorectal Cancer
Efficacy/Safety Study of Bevacizumab,Capecitabine,Oxaliplatin to Metastatic Colorectal Adenocarcinoma Elderly Patients.
The purpose of this study is to determine whether bevacizumab, capecitabine and oxaliplatin are an effective and safe first line of treatment for elderly patients with metastatic colorectal adenocarcinoma.
- Trial name
- BECOX (NCT01067053)
- Testing
- bevacizumab, capecitabine, oxaliplatin
- Where
- 15 sites in Spain
- Volunteers
- 69 people
- Sponsor
- Grupo Espanol Multidisciplinario del Cancer Digestivo
Colorectal Cancer
MRI in Predicting Response in Patients Receiving Combination Chemotherapy and Bevacizumab For Advanced or Metastatic Colorectal Cancer
RATIONALE: Drugs used in chemotherapy, such as fluorouracil, leucovorin, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00602329
- Testing
- bevacizumab, fluorouracil, leucovorin calcium
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Abramson Cancer Center at Penn Medicine